FCCC LOGO Faculty Publications
Greenberg PL , Stone RM , Al-Kali A , Barta SK , Bejar R , Bennett JM , Carraway H , De Castro CM , Deeg HJ , DeZern AE , Fathi AT , Frankfurt O , Gaensler K , Garcia-Manero G , Griffiths EA , Head D , Horsfall R , Johnson RA , Juckett M , Klimek VM , Komrokji R , Kujawski LA , Maness LJ , O'Donnell MR , Pollyea DA , Shami PJ , Stein BL , Walker AR , Westervelt P , Zeidan A , Shead DA , Smith C
Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
J Natl Compr Canc Netw. 2017 Jan;15(1) :60-87
Back to previous list
The myelodysplastic syndromes (MDS) comprise a heterogenous group of myeloid disorders with a highly variable disease course. Diagnostic criteria to better stratify patients with MDS continue to evolve, based on morphology, cytogenetics, and the presence of cytopenias. More accurate classification of patients will allow for better treatment guidance. Treatment encompasses supportive care, treatment of anemia, low-intensity therapy, and high-intensity therapy. This portion of the guidelines focuses on diagnostic classification, molecular abnormalities, therapeutic options, and recommended treatment approaches.
Greenberg, Peter L Stone, Richard M Al-Kali, Aref Barta, Stefan K Bejar, Rafael Bennett, John M Carraway, Hetty De Castro, Carlos M Deeg, H Joachim DeZern, Amy E Fathi, Amir T Frankfurt, Olga Gaensler, Karin Garcia-Manero, Guillermo Griffiths, Elizabeth A Head, David Horsfall, Ruth Johnson, Robert A Juckett, Mark Klimek, Virginia M Komrokji, Rami Kujawski, Lisa A Maness, Lori J O'Donnell, Margaret R Pollyea, Daniel A Shami, Paul J Stein, Brady L Walker, Alison R Westervelt, Peter Zeidan, Amer Shead, Dorothy A Smith, Courtney eng 2017/01/04 06:00 J Natl Compr Canc Netw. 2017 Jan;15(1):60-87.